Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Benitec Biopharma Inc.NASDAQ: BNTC
Other Non-current Liabilities · Q3 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q3 FY2026 other non-current liabilities was $0, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | -100.0% |
| FY2024 | 2024-06-30 | 38K | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-30 | 0 | — |
Other Non-current Liabilities vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 other non-current liabilities of $0 is the 9th highest of the 10 companies compared; the peer median is $2.98M.
- Other non-current liabilities amounts to 0.0% of total assets for BNTC, versus a peer median of 5.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $277.75M | +62455.2% | -84.4% | 52.7% | |
| Dec 2025 | $171.64M | +23.8% | +246.4% | 32.1% | |
| Mar 2026 | $34.14M | +463.3% | +2700.0% | 31.2% | |
| Mar 2026 | $14.6M | +341.4% | — | 5.4% | |
| Mar 2026 | $2.98M | +2090.4% | +83.7% | 18.9% | |
| Mar 2026 | $2.95M | +415.0% | +87.3% | 5.2% | |
| Mar 2026 | $409K | +702.0% | — | 0.2% | |
| Mar 2026 | $25K | -98.5% | -67.6% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BNTC) | $2.98M | +439.1% | +85.5% | 5.4% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.